about
Abetalipoproteinemia: two case reports and literature reviewAlstrom syndrome (OMIM 203800): a case report and literature reviewPitavastatin in cardiometabolic disease: therapeutic profileFibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reductionStatins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trialsPeroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosisCombined therapy with statins and fibrates for people with dyslipidaemiaStatins for dyslipidemia in HIV/AIDS patients on antiretroviralsPharmacological interventions for treating dyslipidemia in patients with HIV infectionStatins for dyslipidemia in HIV/AIDS patients on antiretroviralsCombined therapy with statins and fibrates for people with dyslipidaemiaFructose, insulin resistance, and metabolic dyslipidemiaRole of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?Common variants at 30 loci contribute to polygenic dyslipidemiaEzetimibe therapy: mechanism of action and clinical updateGenome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemiaImpact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemiaNaringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistanceEffects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefitRecommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 updateManagement of dyslipidaemiaThe role of dyslipidemia and statins in venous thromboembolismEffects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot studyBinary classification of dyslipidemia from the waist-to-hip ratio and body mass index: a comparison of linear, logistic, and CART modelsThe pivotal role of cholesterol absorption inhibitors in the management of dyslipidemiaTreatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease.Antiretroviral therapy and dyslipidaemia: unlocking the code.The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemiaCommon medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Dyslipidaemia in the Middle East: Current status and a call for actionHypercholesterolemia Tunes Hematopoietic Stem/Progenitor Cells for Inflammation and AtherosclerosisTriglyceride-rich lipoproteins as a causal factor for cardiovascular diseaseTriglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?Nutraceuticals and Bioactive Components from Fish for Dyslipidemia and Cardiovascular Risk Reduction2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumabCardiovascular risk stratification in familial hypercholesterolaemiaThe Intestinal Microbiota in Metabolic DiseaseDiabetes DyslipidemiaClinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
P921
Q21202911-7888913C-4A6F-4756-BF7A-71CC88292FFFQ21202955-26E086B4-82A0-437E-AA24-FBA41BCA4917Q21246037-D53DCAFD-9E23-4EE0-9726-1CCC2ABEA3A0Q21246041-4883A9F2-467F-4330-9B11-E73E02E10BACQ21261910-813C96A1-D61F-4E1C-B7F7-9FA6BA978429Q22004166-968E683C-1D50-4626-BBAC-2940DE48012FQ24195172-E0039F40-ECCB-4B71-B4DC-345DDDCCCF29Q24198991-914F01D6-D6E3-4CAB-A849-6CC1E9835B1CQ24236121-70872B1A-286D-4245-AC33-1F8C3CB14DCBQ24240943-9CFBA417-D1A8-430F-8A91-DF6231836638Q24243737-F692FE38-1D9D-4433-972F-7BEB07E7327BQ24556527-68B79CCF-5B71-46C2-89AB-4DBB407E816AQ24564203-092800A0-CB6D-40D1-9529-B73DD137D268Q24598765-14CA0A8A-0C84-4171-85F0-F605E7EA0767Q24630302-1BF4855A-019E-47A9-9184-01A4AB5D4E44Q24643127-73C21B31-46F6-4D7E-A6B9-4E99AA5D2E82Q24645182-CD2C332B-912A-4403-BB98-351714BE1D1CQ24648189-F6D1BD7F-ACC0-4E2D-B33C-73AAA8694EDCQ24650533-ACD2187B-1607-4C51-BA32-1BA59616228CQ24669896-A05EECE3-7325-4A8F-BA64-2A705C15BE5FQ24673745-FB038E0F-0FA0-4C3E-979C-A77ED020656CQ24793360-4C741A01-6C15-4BC8-B19F-90CD8BBB8250Q24793945-8D277F0A-3B5A-4D18-8711-927A1142A00BQ24795419-8A857414-7318-417E-8226-D167AB07F509Q24805607-B291A6D6-E8AD-434E-B58A-0BB8C2EFF313Q24812046-73D625DC-EE53-4796-8DCB-2EF22CAEB964Q25256933-AE46F4E9-46CA-4B0A-98CF-8156E8C6560DQ26738554-752D0A55-EA34-40F6-9FD8-1438BD9F352FQ26740253-E0DC09CB-29C8-4F38-A908-8F49ECD12CD9Q26741558-34A0E8EE-FF5F-478A-84FE-1CE35B47CA18Q26742064-D7296C6F-A784-4E08-A872-EE3D443246CCQ26745946-895ADF01-1D9B-4BB4-8345-0FB550A494DCQ26746279-401F43D2-27A7-4BC1-A5F7-AF73001AEAFDQ26747475-4C1D310E-9113-426C-B816-F81F01668D11Q26747559-590B42D0-0BB2-42D5-A543-66A64D0F2DC7Q26747776-A238E31C-9C46-4C34-91F7-4277FD780052Q26749104-4A57474A-E52F-4F50-9EBB-08A43312CA1CQ26750612-51404226-63F8-46AF-9140-A881F0AC3A30Q26750905-CEC6FFAC-50E4-405A-866E-018DEA1960C8Q26752950-EAB0D1F5-ED9E-4C0D-95D9-5C1C6400A2B7
P921
description
abnormalities in the serum levels of lipids
@en
résultat d'examen biologique
@fr
name
anomalie lipidique
@fr
dyslipidemias
@en
type
label
anomalie lipidique
@fr
dyslipidemias
@en
altLabel
dyslipidemia
@en
prefLabel
anomalie lipidique
@fr
dyslipidemias
@en
P486
P672
P486
P672
C18.452.584.500